CareDx

CareDx (operating at caredx.com) is a precision diagnostics and digital health platform engineered for transplant and specialty oncology care. Founded in 1998 by Jay Wohlgemuth, MD, and headquartered in Brisbane, California, CareDx specializes in molecular testing, workflow tools, and patient services designed to address the complexities of organ transplant and cell therapy. Unlike traditional diagnostic approaches, CareDx integrates advanced testing with digital health solutions to streamline care pathways, reduce complications, and improve patient outcomes. Under the hood, the company leverages proprietary molecular diagnostics, regulatory-compliant quality management systems, and AI-driven analytics to deliver actionable insights for clinicians. This allows transplant centers, hospitals, and specialty oncology providers to enhance diagnostic accuracy, optimize treatment plans, and mitigate risks associated with organ rejection or graft failure. Backed by $138 million in funding from investors like Intel and UBS, CareDx has positioned itself as a leading innovator in precision medicine, serving both domestic and international markets.